Licoflavone B Suppresses Influenza A Virus by Targeting the Viral RNA-Dependent RNA Polymerase (RdRp)
Viruses · 24.08.2025 · 17 (9) · 1157
DOI: 10.3390/v17091157 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, online erschienen am 24.08.2025. Verfasst von Pu Fan und 14 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China. Hauptthemen laut MEDLINE: Flavones, Influenza B virus, Orthomyxoviridae Infections, RNA-Dependent RNA Polymerase. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Beijing Rising Stars of Science and Technology Program, Beijing Nova Program.
Abstract (Originalsprache)
Influenza A virus pandemics pose a persistent global health threat, and emerging antiviral resistance underscores the critical importance of developing novel broad-spectrum therapeutic agents. Building on licorice’s (Glycyrrhiza spp.) historical use in traditional Chinese medicine for respiratory infections—as documented in the Chinese Guidelines for Diagnosis and Treatment of Influenza—and its demonstrated anti-SARS-CoV-2 activity, we identified licoflavone B as a potent anti-influenza agent, bridging ethnopharmacological knowledge with mechanistic validation. In this study, we identified licoflavone B, a natural flavonoid derived from licorice (Glycyrrhiza spp.), as a potent inhibitor of diverse influenza viruses, including multiple influenza A subtypes and type B virus. Mechanistic studies revealed that licoflavone B selectively targets the viral RNA-dependent RNA polymerase (RdRp), effectively suppressing viral replication. The compound exhibits a favorable selectivity index (SI = 14.9–29.9), indicating a promising therapeutic window. Molecular docking simulations identified potential binding interactions between licoflavone B and regions of the RdRp complex, which were further validated by dose-dependent inhibition of viral nucleoprotein (NP) and polymerase subunit PB2 expression in Western blot and immunofluorescence assays. In addition, licoflavone B maintained broad-spectrum antiviral activity against multiple influenza strains, including H1N1 (A/Puerto Rico/8/34), H3N2 (A/Darwin/9/2021), and a clinical influenza B isolate (B/Beijing/ZYY-B18/2018). These findings position licoflavone B as a promising lead compound for developing next-generation, broad-spectrum antiviral therapies against influenza and potentially other viruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, China.
- Academy of Military Medical Sciences, Beijing 100071, China.
- State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medical Sciences, Beijing 100071, China.
ORCID-Profile: Peng Lv, Sen Zhang, Tao Jiang, Xiangyang Chi
Förderung
- Beijing Rising Stars of Science and Technology Program
- Beijing Nova Program
Zitieren
APA
Fan, P., Lv, P., Zhang, S., Zhu, Z., Qian, K., Han, J., Cui, Y., Feng, Y., Li, Z., Qiang, L., Dong, Y., Fang, T., Jiang, T., Yu, C., & Chi, X. (2025). Licoflavone B Suppresses Influenza A Virus by Targeting the Viral RNA-Dependent RNA Polymerase (RdRp). Viruses, 17(9), 1157. https://doi.org/10.3390/v17091157
Vancouver
Fan P, Lv P, Zhang S, Zhu Z, Qian K, Han J, et al. Licoflavone B Suppresses Influenza A Virus by Targeting the Viral RNA-Dependent RNA Polymerase (RdRp). Viruses. 2025;17(9):1157. doi:10.3390/v17091157
BibTeX
@article{Fan2025,
author = {Fan, Pu and Lv, Peng and Zhang, Sen and Zhu, Zheng and Qian, Kewen and Han, Jin and Cui, Yue and Feng, Ye and Li, Zeya and Qiang, Li and Dong, Yunzhu and Fang, Ting and Jiang, Tao and Yu, Changming and Chi, Xiangyang},
title = {Licoflavone B Suppresses Influenza A Virus by Targeting the Viral RNA-Dependent RNA Polymerase (RdRp)},
journal = {Viruses},
year = {2025},
volume = {17},
number = {9},
pages = {1157},
doi = {10.3390/v17091157}
}
EUVIMED